Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A

The purpose of this study is to describe the pharmacokinetics (PK) of BAY94-9027(the test drug). Pharmacokinetics means that we will measure how well the study drug corrects the factor VIII levels in your blood and how long it takes for the levels to fall back to your baseline level. The study is also designed to determine if the pharmacokinetics of BAY94-9027 change following repeat dosing over 8 weeks, determine if BAY94-9027 is safe, tolerable, and effective for the treatment of severe hemophilia A and define the appropriate dose of BAY94-9027. Two doses of BAY94-9027 will be studied.

The first 8 subjects enrolled in the study (cohort 1) will receive a low dose (25 IU/kg) and will be treated 2 days a week for 8 weeks (total of 16 doses). The second 8 subjects (cohort 2) will receive a higher dose and will be treated 1 day a week for 8 weeks (total 8 doses). All subjects will receive a single dose of rFVIII (Bayer Kogenate FS) to determine the PK by measuring blood levels for 2 days before they start the study drug BAY94-9027. Factor VIII blood levels for BAY94-9027 will be measured for 7 days after the first and last dose to see describe the PK. Safety & tolerability assessment include vital signs, coagulation and hematological parameter, clinical chemistry, measurement of FVIII inhibitor and polyethylene glycol (PEG) antibodies will be done during the course of the study.

Study Overview

• Status: Completed
• Conditions: Hemophilia A
• Intervention / Treatment: Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Davis, California, United States, 95616
  • Massachusetts
    • Boston, Massachusetts, United States, 02115-6195
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
  • New York
    • Syracuse, New York, United States, 13210

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Male subjects with severe hemophilia A (documented plasma baseline Factor VIII level <1 %)
• >/= 18 but </= 65 years of age
• Previously treated with Factor VIII concentrate(s) for a minimum of 150 exposure days (as supported by the subject's medical history)
• Immunocompetent with a CD4+ lymphocyte count > 400/mm³
• Signed informed consent from subject

Exclusion Criteria:

• Documented history of inhibitor to Factor VIII with a titer >/= 0.6 BU (Biological Unit), by the Nijmegen modified assay. However, subjects with a maximum historical titer of </= 1.0 BU with the classical Bethesda assay on a single measurement but with at least 3 subsequent successive negative results (< 0.6 BU) thereafter are eligible.
• Unable to stop Factor VIII treatment to complete a minimum 72 hour washout
• Current evidence of inhibitor to Factor VIII with a titer >/= 0.6 BU, measured at the time of screening
• Abnormal renal function (serum creatinine > 1.5 times the upper limit of the normal range)
• Total bilirubin > 1.5 times the upper limit of the normal range
• Active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels > 2 times the upper limit of the normal range)
• Any concomitant coagulation disorder other than hemophilia A (including lupus anticoagulant)
• Platelet count < 100,000/mm³
• Within the last 3 months prior to study entry or during the study will be treated with an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a interferon, steroids, rituximab, etc)
• Any subject who requires major surgery during study period. Minor procedures may be approved if discussed in advance with the medical expert.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1	Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222); Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
Experimental: Arm 2	Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)); Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events collection		Up to 8 weeks
Safety as assessed by measuring immunogenicity	Antibodies to FVIII, polyethylene glycol (PEG) and BAY94-9027	Up to 8 weeks
Area under the plasma concentration vs time curve from time 0 to the last data point (AUC0-tlast)		Up to 8 weeks
Area under the plasma concentration vs time curve from zero to infinity after single (first) dose (AUC0-inf)		Up to 8 weeks
Maximum drug concentration in plasma (Cmax)		Up to 8 weeks
Half-life associated with the terminal slope (t1/2)		Up to 8 weeks
Time to reach maximum drug concentration in plasma after single (first) dose (Tmax)		Up to 8 weeks
Mean residence time (MRT)		Up to 8 weeks
Total body clearance (CL)	Total body clearance of drug from plasma (volume/time) or (volume/time/body weight) or ((volume/time)*(1.73/body surface area)) calculated after intravenous administration	Up to 8 weeks
Apparent volume of distribution at steady state (Vss)	Based on the chromogenic, one-stage and PEG capture assays	Up to 8 weeks
Incremental recovery of FVIII	Recovery was assessed using two different assays (chromogenic and one-stage assay)	Up to 8 weeks

Collaborators and Investigators

• Sponsor: Bayer

Publications and helpful links

General Publications

• Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96. doi: 10.1111/jth.12506.

Study record dates

Study Major Dates

• Study Start (Actual): October 13, 2010
• Primary Completion (Actual): October 10, 2011
• Study Completion (Actual): October 10, 2011

Study Registration Dates

• First Submitted: July 13, 2010
• First Submitted That Met QC Criteria: August 18, 2010
• First Posted (Estimate): August 19, 2010

Study Record Updates

• Last Update Posted (Actual): September 7, 2018
• Last Update Submitted That Met QC Criteria: September 6, 2018
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics
• Additional Relevant MeSH Terms: Hematologic Diseases; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Blood Coagulation Disorders; Hemophilia A; Coagulants; Factor VIII
• Other Study ID Numbers: 13401 (Other Identifier: City of Hope Medical Center)